Related references
Note: Only part of the references are listed.The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era
Bradford S. Hoppe et al.
PRACTICAL RADIATION ONCOLOGY (2020)
Dose-response relationships for radiation-related heart disease: Impact of uncertainties in cardiac dose reconstruction
Georgios Ntentas et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy
Chelsea C. Pinnix et al.
JAMA NETWORK OPEN (2020)
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma
Tim M. Illidge et al.
BLOOD ADVANCES (2020)
Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
Georgios Ntentas et al.
PRACTICAL RADIATION ONCOLOGY (2019)
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group
Michael Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma
Alison Starke et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc P. E. Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines
Frederika A. van Nimwegen et al.
BLOOD (2017)
Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma
Frederika A. van Nimwegen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
How Does Cardiovascular Disease First Present in Women and Men? Incidence of 12 Cardiovascular Diseases in a Contemporary Cohort of 1 937 360 People
Julie George et al.
CIRCULATION (2015)
Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
David J. Cutter et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma
John Radford et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma
Maja V. Maraldo et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Cardiovascular Disease After Hodgkin Lymphoma Treatment 40-Year Disease Risk
Frederika A. van Nimwegen et al.
JAMA INTERNAL MEDICINE (2015)
Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
David J. Cutter et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG)
Lena Specht et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy
B. A. Campbell et al.
ANNALS OF ONCOLOGY (2012)
DOSIMETRIC BENEFITS OF INTENSITY-MODULATED RADIOTHERAPY COMBINED WITH THE DEEP-INSPIRATION BREATH-HOLD TECHNIQUE IN PATIENTS WITH MEDIASTINAL HODGKIN'S LYMPHOMA
Amaury Paumier et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Radiotherapy for Early Mediastinal Hodgkin Lymphoma According to the German Hodgkin Study Group (GHSG): The Roles of Intensity-Modulated Radiotherapy and Involved-Node Radiotherapy
Julia Koeck et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Risk of Developing Cardiovascular Disease After Involved Node Radiotherapy Versus Mantle Field for Hodgkin Lymphoma
Maja V. Maraldo et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Effective Dose Reduction to Cardiac Structures Using Protons Compared With 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma
Bradford S. Hoppe et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
Ralph M. Meyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma
S. F. Barrington et al.
ANNALS OF ONCOLOGY (2011)
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Andreas Engert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Increased Risk of Stroke and Transient Ischemic Attack in 5-Year Survivors of Hodgkin Lymphoma
Marie L. De Bruin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy
Sten Myrehaug et al.
LEUKEMIA & LYMPHOMA (2008)
A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk
Eng-Siew Koh et al.
RADIATION ONCOLOGY (2007)
Late cardiotoxicity after treatment for Hodgkin lymphoma
Berthe M. P. Aleman et al.
BLOOD (2007)
Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study
Anthony J. Swerdlow et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Cardiac toxicity of mediastinal radiotherapy: Which are the critical structures?
D Vordermark et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Long-term cause-specific mortality of patients treated for Hodgkin's disease
BMP Aleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger
AK Ng et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The involved field is back: issues in delineating the radiation field in Hodgkin's disease
J Yahalom et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
